Search

Displaying results 9471 - 9480 of 10000 in total
  1. Drug

    GLPG-0492

    go.drugbank.com/drugs/DB12461
    Investigational

    Glpg0492 is under investigation in clinical trial NCT01130818 (First-in-Human Single Ascending Dose of GLPG0492).

  2. Drug

    Izuralimab

    go.drugbank.com/drugs/DB18933
    Investigational

    Izuralimab is under investigation in clinical trial NCT05879185 (A Study of Xmab23104 in People With Sarcoma).

  3. Drug

    CM-4307

    go.drugbank.com/drugs/DB15414
    Investigational

    CM-4307 is under investigation in clinical trial NCT03602495 (Donafenib in 131I-Refractory Differentiated Thyroid Cancer).

  4. Drug

    Ethylhexylglycerin

    go.drugbank.com/drugs/DB14557
    Investigational

    An emollient solvent with antimicrobial activity.

  5. Drug

    Mebhydrolin

    go.drugbank.com/drugs/DB13808
    Investigational

    Mebhydrolin is an antihistamine agent.[A275123]

  6. Drug

    Pidotimod

    go.drugbank.com/drugs/DB11364
    Investigational

    Pidotimod is a synthetic dipeptide with immunomodulatory properties.

  7. Drug

    Avadomide

    go.drugbank.com/drugs/DB14857
    Investigational

    Avadomide is under investigation in clinical trial NCT02031419 (Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma).

  8. Drug

    Cergutuzumab amunaleukin

    go.drugbank.com/drugs/DB14874
    Investigational

    Cergutuzumab amunaleukin is under investigation in clinical trial NCT02004106 (A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid

  9. Drug

    BMS-813160

    go.drugbank.com/drugs/DB16240
    Investigational

    BMS-813160 is under investigation in clinical trial NCT03496662 (BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

  10. Drug

    Telazorlimab

    go.drugbank.com/drugs/DB16374
    Investigational

    Telazorlimab is under investigation in clinical trial NCT03568162 (Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis).